Corresponding Author: Anthony B. Daniels, MD, MSc, Division of Ocular Oncology and Pathology, Department of Ophthalmology and Visual Sciences, Vanderbilt Eye Institute, Vanderbilt University Medical Center, 2311 Pierce Ave, Ste 2252, Nashville, TN 37205 (anthony.b.daniels@vumc.org).
Published Online: January 21, 2021. doi:10.1001/jamaophthalmol.2020.4675
Conflict of Interest Disclosures: Dr Froehler has received grants from the National Institutes of Health, Genentech, Medtronic, Stryker, Microvention, and Penumbra and personal fees from Genentech, Medtronic, Stryker, Balt, Cerenovus, Viz.ai, and Corindus. Dr Daniels has received grants from the National Eye Institute and Research to Prevent Blindness Foundation during the conduct of the study and grants from Spectrum Pharmaceuticals and Alcon Research Institute outside the submitted work; and has a patent with Vanderbilt University Medical Center. No other disclosures were reported.
Funding/Support: This work was supported by grant K08 EY 027464 from the National Eye Institute (Dr Daniels), by a Research to Prevent Blindness Career Development Award (Dr Daniels), and by an unrestricted grant from Research to Prevent Blindness to the Vanderbilt Department of Ophthalmology and Visual Sciences.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank the mother of the patient for granting permission to publish this information.